04-28-2026 Breathe Biologics, Inc. Announces Successful Submission of Amendment #28 for IND 19757

04-03-2026 Breathe Biologics, Inc. Announces IND Amendment for IND Transfer in eCTD Format

03-22-2026 Breathe Biologics, Inc. Announces Filing of IND Amendment for RMAT Designation with FDA 

02-27-2026 Breathe Biologics, Inc. names Ed Johnson as Chief Executive Officer

11-09-2022 Therapeutic Solutions International Launches Spin-Off Breathe Biologics Aimed at Curing Chronic Obstructive Pulmonary Disease (COPD)